Vicore Pharma to Participate in the Jefferies Global Healthcare Conference
Stockholm, Sweden & Cambridge, Mass., November 10, 2026 – Vicore Pharma Holding AB (Nasdaq Stockholm: VICO, Nasdaq US: VCRE), a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the Jefferies Global Healthcare Conference.
Location: London, UK
Format: Fireside chat and 1×1 meetings
Date and time: Thursday, November 19, 2026, 12:00–12:25 PM GMT
Participants:
- Ahmed Mousa, Chief Executive Officer
- Hans Jeppsson, Chief Financial Officer
- Jimmie Hofman, Chief Business Officer
- Bernt van den Blink, Chief Medical Officer
- Rob Slack, Chief Scientific Officer
Webcast: Link
For further information, please contact:
Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com
About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company’s lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com
0 kommentarer
Kommentera nyheten
När du kommenterar ett pressmeddelande publiceras din kommentar även i en speglad tråd under Börssnack så att alla i forumet kan delta i diskussionen!
Logga in eller skapa ett gratis konto för att kommentera nyheten!